TRAVATAN Z

Peak

travoprost

NDAOPHTHALMICSOLUTION/DROPS
Approved
Sep 2006
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20

Mechanism of Action

acid, a prostaglandin analog is a selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.

Pharmacologic Class:

Prostaglandin Analog

Clinical Trials (5)

NCT07400926N/ARecruiting

Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

Started Dec 2025
30 enrolled
Open Angle Glaucoma (OAG)Ocular Hypertension (OH)
NCT07075718Phase 2/3Recruiting

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Started Jun 2025
610 enrolled
Glaucoma
NCT06152861Phase 2Unknown

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Started Nov 2023
250 enrolled
Open Angle GlaucomaOcular Hypertension
NCT06066645Phase 3Recruiting

Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone

Started Sep 2023
230 enrolled
Glaucoma, Open-Angle
NCT06061718Phase 3Active Not Recruiting

Travoprost Intraocular Implant in Conjunction With Cataract Surgery

Started Sep 2023
60 enrolled
Open Angle GlaucomaOcular Hypertension

Loss of Exclusivity

LOE Date
Oct 13, 2029
43 months away
Patent Expiry
Oct 13, 2029

Patent Records (3)

Patent #ExpiryTypeUse Code
8323630
Sep 20, 2027
Product
8388941
Sep 20, 2027
Product
8268299
Oct 13, 2029
Product